Complementary effect of Roe's congenital heart disease treatment compared to Wade's

Published Date: 16 Feb 2023

As more states repeal or restrict abortion laws, the number of patients, the number of workers needed, and the cost of heart disease will increase. How should hospitals and policy makers prepare?

Read Full News

Latest News

Atorvastatin Cuts Major CV Events by 30% in Older Adults in STAREE

Statin use for primary cardiovascular prevention in adults aged 70 years or older is supported by data from STAREE, although treatment did not prolong disability-free survival.

Milvexian Fails to Reduce CV Events After ACS

Patients in the phase 3 LIBREXIA ACS trial showed no reduction in cardiovascular events after acute coronary syndrome.

Phase 3 Eplontersen Trial Results Disappoint

Despite a major reduction in transthyretin amyloid deposits, eplontersen, a drug that reduces TTR production, did not reduce events associated with TTR amyloidosis in a phase 3 trial.

DOACs Benefit AF Patients With Intermediate Stroke Risk

Anticoagulation reduced adverse clinical events in patients with atrial fibrillation at intermediate stroke risk, without an apparent increase in major bleeding.

Heart Failure Drug May Not Improve Exercise Fitness in nHCM

A heart failure drug combination may not improve exercise capacity in patients with nonobstructive hypertrophic cardiomyopathy but is associated with favorable cardiac structural remodeling.

Mounjaro FDA-Approved to Reduce Cardiovascular Risk in T2D

Lilly's Mounjaro (tirzepatide) is now approved to reduce cardiovascular risk in adults with type 2 diabetes.

Todays Updates

Faster 1-Hour MI Rule-Out Is Safe

The 1-hour troponin pathway was safely implemented in a real-world study but did not impact workflow in busy emergency departments.

Edoxaban Falls Short After Intracranial Hemorrhage in AF

Edoxaban reduced ischemic stroke after intracranial hemorrhage in patients with AF, but excess hemorrhagic stroke and major bleeding offset the benefit.

Drug Benefit Seen in Nonobstructive HCM

A multicenter phase 3 trial has associated a cardiac myosin inhibitor with meaningful clinical benefit in nonobstructive HCM, for which there has been no effective therapies.

Tailored Approach Shortens Endocarditis Therapy

Tailored antibiotic therapy for infective endocarditis was associated with a significant reduction in treatment duration, according to an open-label multicenter trial.

Todays Updates

Faster 1-Hour MI Rule-Out Is Safe

The 1-hour troponin pathway was safely implemented in a real-world study but did not impact workflow in busy emergency departments.

Edoxaban Falls Short After Intracranial Hemorrhage in AF

Edoxaban reduced ischemic stroke after intracranial hemorrhage in patients with AF, but excess hemorrhagic stroke and major bleeding offset the benefit.

Drug Benefit Seen in Nonobstructive HCM

A multicenter phase 3 trial has associated a cardiac myosin inhibitor with meaningful clinical benefit in nonobstructive HCM, for which there has been no effective therapies.

Tailored Approach Shortens Endocarditis Therapy

Tailored antibiotic therapy for infective endocarditis was associated with a significant reduction in treatment duration, according to an open-label multicenter trial.

Latest News

Statin use for primary cardiovascular prevention in adults aged 70 years or older is supported by data from STAREE, although treatment did not prolong disability-free survival.

Patients in the phase 3 LIBREXIA ACS trial showed no reduction in cardiovascular events after acute coronary syndrome.

Despite a major reduction in transthyretin amyloid deposits, eplontersen, a drug that reduces TTR production, did not reduce events associated with TTR amyloidosis in a phase 3 trial.

Anticoagulation reduced adverse clinical events in patients with atrial fibrillation at intermediate stroke risk, without an apparent increase in major bleeding.

A heart failure drug combination may not improve exercise capacity in patients with nonobstructive hypertrophic cardiomyopathy but is associated with favorable cardiac structural remodeling.

Lilly's Mounjaro (tirzepatide) is now approved to reduce cardiovascular risk in adults with type 2 diabetes.

News All Time

Gray-Market Retatrutide: Less Weight Loss, More CV Effects

Gray-market retatrutide use is increasing, but unapproved products aren’t delivering expected results. Its manufacturer Eli Lilly is calling for increased oversight.

Preclinical Vascular Impairment Tied to Mortality

New criteria identifies preclinical vascular cognitive impairment in adults without dementia or stroke and linked it to higher cardiovascular risk and mortality.

Professional Corner: AMA Awards $1 Million in Grants

The AHA opens its health tech competition, AMA awards $1 million in community grants, and pediatricians call for stronger protections for children at the US border.

Vutrisiran May Stabilize Right Ventricle Function in ATTR-CM

Right ventricular dysfunction is linked to worse outcomes in patients with transthyretin amyloidosis with cardiomyopathy; vutrisiran treatment may help stabilize right ventricular function.

Inhaling Cannabis Tied to Less Cardiac Ectopy in Adults

Adults without a history of cardiac arrhythmias have less cardiac ectopy on days they were randomly assigned to inhale cannabis than on days they abstained.

An Accordion’s Unlikely Assist in Heart Research

Researchers applied the physics of the instrument to a new device that reproduces the heart’s complex blood flow waveforms.

Common ASM Tied to Twofold Thromboembolic Risk With DOACs

Levetiracetam has been linked to an increased thromboembolic risk among adults with epilepsy receiving DOACs, but experts caution that, at this point, the finding is not practice-changing.

Mildly Elevated Ketones May Protect Kidneys in T2D

In patients with type 2 diabetes, mildly elevated blood ketone body levels are associated with a lower risk of developing kidney complications, a study finds.

Mushrooms Gain Ground in Medicine Despite Limited Evidence

Mushroom compounds show potential across cancer, metabolic, and neurologic research, but most evidence remains preclinical and larger clinical trials are still needed.

Doctors Need Friends Outside Medicine, and It’s Not Easy

Doctors may find their closest friends in medicine and have little time for others. But experts say friendships outside the medical bubble matter more than ever.

Cardioprotection Rarely Used in Adults With Blood Cancers

Few adults on anthracycline chemotherapy for hematologic cancers receive strategies to protect their hearts.

Breakthrough Stroke in AF Linked to Drug Interactions

Patients who experience ischemic stroke despite ongoing oral anticoagulation for atrial fibrillation often have identifiable causes such as drug interactions or non-cardioembolic disease.

Medicine on Screen: 10 Films Doctors May Want to Rewatch

From Alzheimer’s to pandemics, these films show how medicine is lived as much as it is practiced.

Sequential or Simultaneous Therapy in Chronic Kidney Disease

Experts debate the pros and cons of stepwise vs simultaneous therapy for chronic kidney disease in an era of multifactorial treatment choices.

Deep Dive: DPP-4 Inhibitors After the ADA Downgrade

ADA now says limit or discontinue gliptins. Cardiologist Benjamin Scirica, MD, on why sitagliptin still looks safest of the four.

New Tool May Identify Adverse Events in Hospitalized Kids

A new trigger tool can help identify adverse events in hospitalized children, showing good reviewer agreement and aiding the systematic detection of patient harm.

Recommended News For You

Research indicates that extended PSMA therapy is safe and effective for patients with prostate cancer.

ACS Guidelines Expand Lung Cancer Screening Eligibility -- Is That a Good Thing?

Global inequalities found in cancer research funding

EU Adds CAR-T Warning; New Blincyto Indication; Good News in Pancreatic Cancer

What Could This Exploratory 5-Year Survival Data in Adjuvant NSCLC Treatment Mean?

Can the way we talk about cancer change how we interact with the disease?

Early Identification of Ovarian Cancer; Allergy Medicine for NSCLC? Unfavorable Development for Anti-TIGIT Medication?

Recommended Articles For You

Targeting Cancer Stem Cells in Solid Tumors: Mechanisms, Clinical Implications, and Therapeutic Advances 

Tumor-Specific Fluorescent Peptide Navigation in Surgical Oncology 

Understanding the Causes and Symptoms of Cavernous Sinus Thrombosis  

Iron Deficiency Anemia: Challenges in Diagnosis and Treatment 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

The Early Progression of Prostate Cancer Is Not Stopped by Metformin.

2.

Bladder cancer link to explosive ordnance exposure among Army veteran bomb disposal officers

3.

In Biochemically Recurrent Nonmetastatic Prostate Cancer, Apalutamide Presents Its Argument.

4.

A study on lung cancer provides additional proof of the value of screening.

5.

What does it mean for Biden's prostate cancer to be 'aggressive'? A urologic surgeon explains

1.

Genetic Testing in Cancer Prevention: BRCA Mutations and Lynch Syndrome Unlocked

2.

Emicizumab in Infants with Severe Hemophilia A: HAVEN 7 Phase 3b Trial Insights

3.

The Latest Research on Basal Cell Carcinoma: New Developments in Diagnosis and Cure 

4.

Understanding Dasatinib: A Promising Drug for Cancer Treatment 

5.

Guideline Evolution in Benign Hematologic Conditions

1.

Asian Symposium on Advancement in Hematology and Oncology (ASAHO)

2.

International Cancer Conference

3.

Asian Symposium on Advancement in Hematology and Oncology (ASAHO)

4.

Asian Symposium on Advancement in Hematology and Oncology

5.

Asian Symposium on Advancement in Hematology and Oncology

1.

A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part II

2.

Incidence of Lung Cancer- An Overview to Understand ALK Rearranged NSCLC

3.

Navigating the Brain Barrier: The CNS Challenge in ALK+ NSCLC

4.

Efficient Management of First line ALK-rearranged NSCLC - Part III

5.

Efficient Management of First line ALK-rearranged NSCLC - Part VI

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot